

MPH AG: Annual shareholders' meeting in Berlin

Dividend payment increased by +53.8% compared to previous year

Berlin, 30th June 2011 – at the annual general shareholders' meeting of the MPH Mittelständische Pharma Holding AG, which took place yesterday in Berlin, the board of management reported that the expectations in the past year 2010 had been fulfilled. The turnover compared with the previous year 2009 increased by +80.6% and the annual profit by +84.6%. The holders of preferred shares will participate in this success with a dividend of EUR 0.20 per share (as compared with EUR 0.13 for the business year 2009). The dividend of the common share increases to EUR 0.17 (as compared with EUR 0.11 for the business year 2009).

The board of management confirmed the positive perspective for the business year 2011. Over the course of their discourse the board of management addressed the anticipated market development and the successful expansion of the market position. The continued anticipated dynamic growth of the health market that is independent of cyclical influences is a fundamental driving factor. Over the past year the MPH group was able to substantially increase the circle of customers (from 1,600 to 3,500 customers). The reason for this was the extension of the product range (from 169 to 380 products).

All members of the board of management and the supervisory board were granted approval; also all other points of the order of business were unanimously approved and thereby resolved.

The pleasing development of the share prices mirrors the dynamic development of the MPH group. Over the course of the year 2010 the share price increased from EUR 1.62 to EUR 2.43 and is currently at a level above EUR 3.00.

About the MPH Mittelständische Pharma Holding AG:

The company Berlin MPH Mittelständische Pharma Holding AG has concentrated itself strategically on growth segments in the pharmaceutical market. The subsidiary company HAEMATO PHARM AG is primarily involved in the area of human medicine in pharmaceutical products for the therapeutic areas oncology, HIV, rheumatism and neurology. The subsidiary company HAEMATO Vet GmbH supplies the veterinary market with veterinary pharmaceutical and veterinary medical products, as well as animal feed supplements.

The company currently engages roughly 63 employees and in 2010 achieved a turnover of EUR 112.4 million.

Contact:

MPH Mittelständische Pharma Holding AG
Patricia Blechinger
Hubertusallee 73
D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 70

E-Mail: info@mph-ag.de
Web: www.mph-ag.de

Press release



30th June 2011

The company MPH Mittelständische Pharma Holding AG is listed in the open market of the Frankfurt stock exchange (WKN: A0NF69).

Subscribed capital: EUR 38,050,000
Stock exchange listed share type: preferred shares
Number of circulating preferred shares: 19,025,000
ISIN: DE000A0NF697
WKN: A0NF69
Stock exchange code: 93MV

Contact:

MPH Mittelständische Pharma Holding AG
Patricia Blechinger
Hubertusallee 73
D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 70

E-Mail: info@mph-ag.de
Web: www.mph-ag.de